Condition
Neutralizing Antibodies
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Not Yet Recruiting1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07347769Not Yet Recruiting
Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy
NCT04700358Recruiting
Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis
Showing all 2 trials